Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women

Obstetrics and Gynecology

Volumn 106, Issue 5, 2005, Pages 1110-1111

  Draper, Michael W ^a   Plouffe, Leo ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; LETTER; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VAGINA BLEEDING;

ENDOMETRIUM; FEMALE; HUMANS; INDOLES; RESEARCH DESIGN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 27444441835     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000186081.62399.61     Document Type: Letter

References (4)

1. Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF, Constantine G, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-404.
2. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-26.
3. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64.
4. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.